These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 31357404)

  • 1. Inflammation as a Therapeutic Target in Atherosclerosis.
    Nguyen MT; Fernando S; Schwarz N; Tan JT; Bursill CA; Psaltis PJ
    J Clin Med; 2019 Jul; 8(8):. PubMed ID: 31357404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.
    Montarello NJ; Nguyen MT; Wong DTL; Nicholls SJ; Psaltis PJ
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):347-362. PubMed ID: 33170943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the Inflammatory Hypothesis of Coronary Artery Disease.
    Boland J; Long C
    Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary inflammation: why searching, how to identify and treat it.
    Prati F; Marco V; Paoletti G; Albertucci M
    Eur Heart J Suppl; 2020 Jun; 22(Suppl E):E121-E124. PubMed ID: 32523455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Lorenzatti A; Servato ML
    Eur Cardiol; 2018 Aug; 13(1):38-41. PubMed ID: 30310469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab for secondary prevention of coronary artery disease.
    Ortega-Paz L; Capodanno D; Angiolillo DJ
    Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colchicine for the treatment of coronary artery disease.
    Aimo A; Pascual-Figal DA; Barison A; Cediel G; Vicente ÁH; Saccaro LF; Emdin M; Bayes-Genis A
    Trends Cardiovasc Med; 2021 Nov; 31(8):497-504. PubMed ID: 33096241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Colchicine in Acute Coronary Syndromes.
    Vaidya K; Martínez G; Patel S
    Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.